In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Tandem Diabetes Care Inc (NASDAQ: TNDM) closed at $21.55 in the last session, down -1.96% from day before closing price of $21.98. In other words, the price has decreased by -$1.96 from its previous closing price. On the day, 0.99 million shares were traded. TNDM stock price reached its highest trading level at $22.45 during the session, while it also had its lowest trading level at $21.55.
Ratios:
We take a closer look at TNDM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.44. In the meantime, Its Debt-to-Equity ratio is 3.38 whereas as Long-Term Debt/Eq ratio is at 3.22.
On September 08, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.Oppenheimer initiated its Outperform rating on September 08, 2025, with a $22 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 11 ’25 when Sheridan John F bought 10,000 shares for $10.23 per share. The transaction valued at 102,318 led to the insider holds 106,327 shares of the business.
Vosseller Leigh bought 13,720 shares of TNDM for $149,404 on Aug 08 ’25. The EVP & CHIEF FINANCIAL OFFICER now owns 25,580 shares after completing the transaction at $10.89 per share. On Mar 07 ’25, another insider, Kyrillos Jean-Claude, who serves as the EVP & Chief Operating Officer of the company, bought 10,538 shares for $18.12 each. As a result, the insider paid 190,966 and bolstered with 10,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 1461140864 and an Enterprise Value of 1596213888. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.45 while its Price-to-Book (P/B) ratio in mrq is 10.98. Its current Enterprise Value per Revenue stands at 1.585 whereas that against EBITDA is -22.94.
Stock Price History:
The Beta on a monthly basis for TNDM is 1.69, which has changed by -0.42310268 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, TNDM has reached a high of $38.28, while it has fallen to a 52-week low of $9.98. The 50-Day Moving Average of the stock is 12.40%, while the 200-Day Moving Average is calculated to be 24.89%.
Shares Statistics:
According to the various share statistics, TNDM traded on average about 2.02M shares per day over the past 3-months and 1048260 shares per day over the past 10 days. A total of 67.77M shares are outstanding, with a floating share count of 67.10M. Insiders hold about 1.03% of the company’s shares, while institutions hold 112.44% stake in the company. Shares short for TNDM as of 1765756800 were 8176917 with a Short Ratio of 4.05, compared to 1763078400 on 8787092. Therefore, it implies a Short% of Shares Outstanding of 8176917 and a Short% of Float of 16.690001.
Earnings Estimates
The dynamic stock of Tandem Diabetes Care Inc (TNDM) is currently attracting attention from 20.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.2 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.5 and -$3.32 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$0.97, with 22.0 analysts recommending between -$0.58 and -$2.39.
Revenue Estimates
According to 19 analysts,. The current quarter’s revenue is expected to be $276.95M. It ranges from a high estimate of $281.86M to a low estimate of $271.43M. As of. The current estimate, Tandem Diabetes Care Inc’s year-ago sales were $282.65MFor the next quarter, 19 analysts are estimating revenue of $248.8M. There is a high estimate of $261.4M for the next quarter, whereas the lowest estimate is $232.28M.
A total of 23 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $1.01B, while the lowest revenue estimate was $995.78M, resulting in an average revenue estimate of $1B. In the same quarter a year ago, actual revenue was $940.2MBased on 23 analysts’ estimates, the company’s revenue will be $1.1B in the next fiscal year. The high estimate is $1.14B and the low estimate is $1.07B.
